Alkermes heads into its July 27 earnings date with an unusual tension: a stock up 29% in a month, a wave of analyst upgrades, and yet short sellers quietly adding to positions.
The Street's direction of travel has been firmly bullish, but not unanimously so. Mizuho raised its target to $65 on July 2, joining Wells Fargo which lifted to $65 from $44 just days earlier — a 48% jump in Wells Fargo's conviction on valuation. Needham and TD Cowen also moved targets higher over the past two weeks. The outlier is Bank of America Securities, which downgraded to Underperform with a $38 target on June 29 — a sharp contrast with the bulls, and a level now sitting roughly 30% below the current price of $55.22. The mean price target across the Street is $50.19, which the stock has already blown through, suggesting the upgrade cycle has not yet caught up to price action. Bulls anchor on the ALKS 2680 orexin pipeline and the company's integrated development platform; bears at BofA flag competitive headwinds for oveporexton and limited dosage optionality. Valuation multiples reflect the re-rating: the P/E has expanded by nearly 20 points over the past 30 days to 40x, and the P/B ratio has risen by more than 1x over the same period.
Short interest tells a more cautious story than the rally might suggest. Bears hold 11.3% of free float — a high reading for a mid-cap biotech — and that figure has crept up 2.1% over the past week and 4.4% over the past month. The ORTEX short score has drifted to 64.5, its highest level in the current tracking window, edging up almost daily since late June. What makes the positioning notable is that it is growing a rising stock, rather than the more typical pattern of shorts covering into strength. The FINRA official figure as of June 15 put days-to-cover at 9.5, giving this a meaningful squeeze potential should the earnings catalyst disappoint the bears.
The borrow market is not adding pressure, however. Availability is running at roughly 418% — meaning there are more than four times as many shares available to borrow as are currently shorted — well within the normal range and close to the year's loosest levels. Borrowing costs are low at 0.46%, essentially unchanged over the past week. That combination tells you shorts are not under squeeze pressure; they can maintain or add to positions cheaply. Options positioning is similarly calm. The put/call ratio is 0.72, only modestly above its 20-day average of 0.68, with a z-score just 0.3 standard deviations elevated. The 52-week high on the PCR is 3.18, so current options flow reflects mild hedging rather than any directional panic.
On the ownership side, one institutional move stands out. First Trust Advisors added over 1.5 million shares in the most recent filing period, becoming a more meaningful holder at 1.78% of shares. Deep Track Capital also built a position, adding 1.59 million shares. BlackRock, already the largest holder at 17% of shares, added a further 365,000 in the quarter to June 30. Insiders have been consistent sellers into the rally — the CMO sold nearly $464,000 worth in early July, and the CLO sold a smaller tranche on July 6 — but these are low-significance transactions consistent with routine plan sales rather than conviction departures. Net insider activity over 90 days is a modest net buy of just under 66,000 shares, so the selling is not yet a red flag.
The last earnings print on May 5 produced a 3.4% gain on the day and 12% over the following five days, the strongest positive reaction in the recent history. With Q2 results due July 27 and the EPS surprise factor scoring at the 99th percentile, the setup heading into the print is whether pipeline execution on ALKS 2680 and the orexin franchise can justify a P/E that has nearly doubled in a month — and whether the BofA bear case or the consensus bull case has better read the competitive landscape.
See the live data behind this article on ORTEX.
Open ALKS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
